^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CIP2A (Cellular Inhibitor Of PP2A)

    i
    Other names: Cellular Inhibitor Of PP2A, Cell Proliferation Regulating Inhibitor Of Protein Phosphatase 2A, Cancerous Inhibitor Of Protein Phosphatase 2A, Cancerous Inhibitor Of PP2A, P90 Autoantigen, Protein CIP2A, NOCIVA, CIP2A, P90
    14d
    Identification of stemness-related glycosylation changes in head and neck squamous cell carcinoma. (PubMed, BMC Cancer)
    A mannose- and galactose-rich glycosylation niche associated with stemness-related proteins was identified.
    Journal
    |
    POU5F1 (POU Class 5 Homeobox 1) • CIP2A (Cellular Inhibitor Of PP2A)
    25d
    ent-8(14),15-Pimaradiene-2β,19-diol, a diterpene from Aleuritopteris albofusca, inhibits growth and induces protective autophagy in hepatocellular carcinoma cells. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    When combined with autophagy inhibitor 3-methyladenine and chloroquine, the cell viability was significantly reduced, suggesting that JXE-23 triggered protective autophagy in hepatoma cells...Our data provided evidence that JXE-23 inhibited cell growth, arrested cells at the G2/M phase, and induced protective autophagy in HepG2 hepatocellular carcinoma cells. JXE-23 may be a potential lead compound for anti-cancer drug development, and autophagy inhibitor treatment may provide an effective strategy for improving its anti-cancer effect.
    Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A) • BECN1 (Beclin 1)
    1m
    Broken chromosomes heading into mitosis: More than one way to patch a flat tire. (PubMed, J Cell Biol)
    Here, we review recent progress in this field of mitotic DNA damage and discuss why multiple mechanisms exist. Future studies in this exciting area will reveal new DNA break responses and inform therapeutic strategies.
    Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A)
    3ms
    Genome-wide transcriptome analysis of Echinococcus multilocularis larvae and germinative cell cultures reveals genes involved in parasite stem cell function. (PubMed, Front Cell Infect Microbiol)
    RNA-Seq analyses on primary cell cultures revealed that metacestode-derived Echinococcus stem cells display an expanded differentiation capability and do not only form differentiated cell types of the metacestode, but also cells expressing genes specific for protoscoleces, adult worms, and oncospheres, including an ortholog of the schistosome praziquantel target, EmTRPMPZQ...Taken together, our analyses provide a robust and comprehensive characterization of the Echinococcus germinative cell transcriptome, demonstrate expanded differentiation capability of metacestode derived stem cells, and underscore the potential of primary germinative cell cultures to investigate developmental processes of the parasite. These data are relevant for studies into the role of Echinococcus stem cells in parasite development and will facilitate the design of anti-parasitic drugs that specifically act on the parasite germinative cell compartment.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CIP2A (Cellular Inhibitor Of PP2A)
    3ms
    CIP2A induces PKM2 tetramer formation and oxidative phosphorylation in non-small cell lung cancer. (PubMed, Cell Discov)
    CIP2A-targeting compounds synergized with glycolysis inhibitor in suppressing cell proliferation in vitro and in vivo. These results indicated that CIP2A facilitates oxidative phosphorylation by promoting tetrameric PKM2 formation, and targeting CIP2A and glycolysis exhibits therapeutic potentials in NSCLC.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CIP2A (Cellular Inhibitor Of PP2A) • PKM (Pyruvate Kinase M1/2)
    4ms
    Exploring the composition of protein-ligand binding sites for cancerous inhibitor of PP2A (CIP2A) by inhibitor guided binding analysis: paving a new way for the Discovery of drug candidates against triple negative breast cancer (TNBC). (PubMed, J Recept Signal Transduct Res)
    The steadiness and tightness of lapatinib with CIP2A inside the stem domain disclosed glutamic acid-318 as the culprit amino acid with the highest electrostatic energy. These results provide clear information on the CIP2A domain capable of ligand binding and validate lapatinib as a promising CIP2A inhibitor in TNBC carcinogenesis.
    Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A)
    |
    lapatinib
    4ms
    DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic Leukemia: Focus on the Genes Involved. (PubMed, Int J Mol Sci)
    Of the 36 patients, only 5 (13.8%) had a normal molecular karyotype, and 31 (86.2%) were found to have various molecular karyotype abnormalities-104 deletions, 90 duplications or amplifications, 29 cases of cnLOH and 7 biallelic/homozygous deletions. We found that 11q22-23 duplication involving the BIRC3, ATM and MLL genes was the most adverse prognostic event in the study cohort.
    Journal
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • BIRC3 (Baculoviral IAP repeat containing 3) • PAX5 (Paired Box 5) • ARID1B (AT-Rich Interaction Domain 1B) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • EP300 (E1A binding protein p300) • IKZF3 (IKAROS Family Zinc Finger 3) • CCL20 (C-C Motif Chemokine Ligand 20) • TCF3 (Transcription Factor 3) • CIP2A (Cellular Inhibitor Of PP2A) • IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • IKZF2 (IKAROS family zinc finger 2) • SH2B3 (SH2B Adaptor Protein 3) • XPA (XPA, DNA Damage Recognition And Repair Factor) • DOCK8 (Dedicator Of Cytokinesis 8) • MEF2C (Myocyte Enhancer Factor 2C) • MEF2D (Myocyte Enhancer Factor 2D) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2) • BTG2 (BTG Anti-Proliferation Factor 2) • PAX3 (Paired Box 3) • RAG1 (Recombination Activating 1) • RUNX2 (RUNX Family Transcription Factor 2) • ZNF384 (Zinc Finger Protein 384)
    6ms
    c-MYC-dependent transcriptional inhibition of autophagy is implicated in cisplatin sensitivity in HPV-positive head and neck cancer. (PubMed, Cell Death Dis)
    Both CIP2A and c-MYC knock-down, as well as pharmacological downregulation of c-MYC, resulted in increased resistance to cisplatin treatment. Our results not only show a novel way by which HPV oncoproteins manipulate the host machinery but also provide more insights into the role of autophagy in chemoresistance, with possible implications for targeted HPV-positive HNC therapy.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CIP2A (Cellular Inhibitor Of PP2A)
    |
    cisplatin
    6ms
    A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors. (PubMed, Proc Natl Acad Sci U S A)
    Moreover, the effectiveness of 5D4 is further enhanced when combined with a PARP1/2 inhibitor talazoparib. Taken together, our findings strongly support the potential use of TopBP1-BRCT7/8 inhibitors as a targeted cancer therapy.
    Journal • PARP Biomarker
    |
    RAD51 (RAD51 Homolog A) • PLK1 (Polo Like Kinase 1) • CIP2A (Cellular Inhibitor Of PP2A) • E2F1 (E2F transcription factor 1)
    |
    TP53 mutation
    |
    Talzenna (talazoparib)
    6ms
    Investigation of Salivary Mir-9 And Serum Cip2a Levels in Fanconi Anemia Patients at High Risk Of Developing Oral Squamous Cell Carcinoma (EHOC 2023)
    Conclusion Our findings indicate that miR-9 and CIP2A may be remarkable biomarkers in the development of OSCC. Since FA patients have a high risk of developing OSCC, close follow-up of the physical examination findings of miR-9 and CIP2A levels can be beneficial.
    Clinical
    |
    CIP2A (Cellular Inhibitor Of PP2A)
    7ms
    CIP2A interacts with AKT1 to promote the malignant biological behaviors of oral squamous cell carcinoma by upregulating the GSK‑3β/β‑catenin pathway. (PubMed, Exp Ther Med)
    In conclusion, CIP2A could interact with AKT1 to promote the malignant biological behaviors of OSCC cells by upregulating the GSK-3β/β-catenin pathway. These findings may provide a targeted therapy for OSCC treatment.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CIP2A (Cellular Inhibitor Of PP2A)
    |
    AKT1 overexpression • CIP2A elevation • CDC42 elevation
    7ms
    Emerging roles of the CIP2A-TopBP1 complex in genome integrity. (PubMed, NAR Cancer)
    TopBP1 has multiple functions as it is a scaffold for proteins involved in DNA replication, transcriptional regulation, cell cycle regulation and DNA repair. Here, we briefly review details of the CIP2A-TopBP1 interaction, its role in maintaining genome integrity, its involvement in cancer and its potential as a therapeutic target.
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CIP2A (Cellular Inhibitor Of PP2A)
    7ms
    CIP2A coordinates phosphosignaling, mitosis, and the DNA damage response. (PubMed, Trends Cancer)
    The CIP2A-TopBP1 complex is also important for clustering fragmented chromosomes at mitosis. Clinically, CIP2A is a disease driver for basal-like triple-negative breast cancer (BL-TNBC) and a promising cancer therapy target across many cancer types.
    Review • Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset) • CIP2A (Cellular Inhibitor Of PP2A)
    |
    BRCA mutation
    8ms
    A virally encoded GPCR drives glioblastoma through feed-forward activation of the SK1-S1P signaling axis. (PubMed, Sci Signal)
    US28 also activated the S1P signaling axis in HCMV-infected cells. This study uncovers central roles for S1P and CIP2A in feed-forward signaling that contributes to the US28-mediated exacerbation of glioblastoma.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CHEK1 (Checkpoint kinase 1) • CIP2A (Cellular Inhibitor Of PP2A) • SPHK1 (Sphingosine Kinase 1)
    9ms
    Celastrol impairs tumor growth by modulating the CIP2A-GSK3β-MCL-1 axis in gastric cancer cells. (PubMed, Aging (Albany NY))
    Our findings highlight that celastrol has therapeutic potential via inducing apoptosis of gastric cancer cells.
    Journal
    |
    MCL1 (Myeloid cell leukemia 1) • CIP2A (Cellular Inhibitor Of PP2A) • GSK3B (Glycogen Synthase Kinase 3 Beta) • ANXA5 (Annexin A5)
    |
    CIP2A elevation
    11ms
    A link between CIP2A and DNA damage response in basal like-triple negative breast cancer (EACR 2023)
    By using a site-specific CRISPR/Cas9 mutagenesis we expect to have an expanded DDR protein network regulated by CIP2A which explain the molecular mechanism essential for BL-TNBC cells survival. Finally, we expect the data to be beneficial in developing a novel targeted therapy for BL-TNBCs.
    Tumor mutational burden • BRCA Biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA (Breast cancer early onset) • CIP2A (Cellular Inhibitor Of PP2A)
    |
    TMB-H • BRCA mutation
    11ms
    Celastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies. (PubMed, Biomed Pharmacother)
    Subsequently, studies of its toxicity and pharmacokinetic properties showed that celastrol has some adverse effects, low oral bioavailability and a narrow therapeutic window. In addition, the current challenges of celastrol and the corresponding therapeutic strategies are also discussed, thus providing a theoretical basis for the development and application of celastrol in the clinic.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • STK11 (Serine/threonine kinase 11) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CIP2A (Cellular Inhibitor Of PP2A) • CASP9 (Caspase 9) • HSF1 (Heat Shock Transcription Factor 1)
    12ms
    Metformin and Nightly Fasting in Women With Early Breast Cancer (clinicaltrials.gov)
    P2b, N=120, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MCL1 (Myeloid cell leukemia 1) • CIP2A (Cellular Inhibitor Of PP2A) • GSK3B (Glycogen Synthase Kinase 3 Beta) • IGFBP3 (Insulin-like growth factor binding protein 3) • CRP (C-reactive protein)
    1year
    Cancer progression by the okadaic acid class of tumor promoters and endogenous protein inhibitors of PP2A, SET and CIP2A. (PubMed, J Cancer Res Clin Oncol)
    This review establishes the concept that inhibition of PP2A activity is a common mechanism of human cancer progression and activation of PP2A activity leads to effective anticancer therapy.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • TNFA (Tumor Necrosis Factor-Alpha) • CIP2A (Cellular Inhibitor Of PP2A) • HOXB13 (Homeobox B13)
    |
    erlotinib
    1year
    The TT Genotype of the KIAA1524 rs2278911 Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma. (PubMed, Cells)
    The evaluation of the SNP 686C > T of the KIAA1524 gene could be used as a diagnostic tool in MM patients at risk of early disease progression and death.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • FGFR3 (Fibroblast growth factor receptor 3) • CCND1 (Cyclin D1) • CIP2A (Cellular Inhibitor Of PP2A)
    1year
    Cip2a induces arginine biosynthesis and promotes tumor progression in non-small cell lung cancer. (PubMed, Mol Carcinog)
    In addition, we found that p53 mutants in NSCLC cells increased Cip2a expression by inhibiting the activity of wild-type p53. Our findings provide new insights into the mechanisms of Cip2a in promoting tumor progression and suggest that Cip2a represents a potential therapeutic target for treating NSCLC.
    Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A)
    |
    TP53 mutation • TP53 wild-type
    1year
    Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin. (PubMed, World J Gastrointest Oncol)
    CIP2A expression could be a novel therapeutic strategy for chemoresistance in GC.
    Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A)
    |
    CIP2A elevation
    |
    oxaliplatin
    1year
    Are population level familial risks and germline genetics meeting each other? (PubMed, Hered Cancer Clin Pract)
    A strong interaction was shown with a polymorphism in the CIP2A gene. The emerging germline landscape of common cancers can be reasonably accommodated by family data on these cancers as to high-risk proportions and age of onset.
    Review • Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • CIP2A (Cellular Inhibitor Of PP2A) • HOXB13 (Homeobox B13)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA1 mutation + BRCA2 mutation • BRCA mutation
    1year
    Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A. (PubMed, Nat Commun)
    Collectively, we discover a unique multi-step hijack and mute protein complex regulation mechanism resulting in tumour suppressor PP2A-B56α inhibition. Further, the results unfold a structural determinant for the oncogenic activity of CIP2A, potentially facilitating therapeutic modulation of CIP2A in cancer and other diseases.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CIP2A (Cellular Inhibitor Of PP2A) • PPP2CA (Protein Phosphatase 2 Catalytic Subunit Alpha 2)
    |
    MYC expression
    over1year
    Establishing a metastasis-related diagnosis and prognosis model for lung adenocarcinoma through CRISPR library and TCGA database. (PubMed, J Cancer Res Clin Oncol)
    The model has important diagnostic and prognostic value for metastatic LUAD and may be useful in clinical applications.
    Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A) • HOXB9 (Homeobox B9)
    over1year
    The Pivotal Role of Protein Phosphatase 2A (PP2A) in Brain Tumors. (PubMed, Int J Mol Sci)
    Interestingly, the review focused on the role of PP2A inhibitors, focusing on CIP2A inhibition, as CIP2A participated in tumor cell growth by stimulating cell-renewal survival, cellular proliferation, evasion of senescence and inhibition of apoptosis. This review suggested CIP2A inhibition as a promising strategy in oncology target therapy.
    Review • Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A)
    over1year
    Weighted gene co-expression network reveals driver genes contributing to phenotypes of anaplastic thyroid carcinoma and immune checkpoint identification for therapeutic targets. (PubMed, Front Oncol)
    Furthermore, we illustrated that ADAM12, RNASE2, and HAVCR2 were predominantly present in the cytoplasm. Our study identified a set of novel ATC-specific genes that were mainly related to cell proliferation, invasion, metastasis, and immunosuppression, which might throw light on molecular mechanisms underlying aggressive phenotypes of ATC and provide promisingly diagnostic biomarkers and therapeutic targets.
    Journal
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CIP2A (Cellular Inhibitor Of PP2A) • TDO2 (Tryptophan 2,3-Dioxygenase) • ADAM12 (ADAM Metallopeptidase Domain 12) • E2F7 (E2F Transcription Factor 7) • MYBL1 (MYB Proto-Oncogene Like 1)
    over1year
    High sensitivity CIP2A detection for oral cancer using a rapid transistor-based biosensor module. (PubMed, J Vac Sci Technol B Nanotechnol Microelectron)
    Sensitivities of 1 × 10 g/ml have been obtained for both detections of pure CIP2A protein and HeLa cell lysate using identical test conditions via serial dilution. The superior time-saving and high accuracy testing provides opportunities for rapid clinical diagnosis in the medical space.
    Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A)
    over1year
    Ethoxysanguinarine directly targets CIP2A to inhibit proliferation and induce autophagy of SGC7901/DDP cells (PubMed, Zhongguo Zhong Yao Za Zhi)
    The above results demonstrated that Eth inhibited the proliferation, induced the apoptosis, and activated the autophagy of SGC7901/DDP cells by targeting CIP2A and then down-regulating PP2A/mTORC1 signaling pathway. This study provided a new target for the treatment of cisplatin-resistant gastric cancer.
    Journal • PARP Biomarker
    |
    CASP3 (Caspase 3) • CIP2A (Cellular Inhibitor Of PP2A) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1) • CASP9 (Caspase 9) • RPS6 (Ribosomal Protein S6) • ANXA5 (Annexin A5) • TRPS1 (Transcriptional Repressor GATA Binding 1)
    |
    cisplatin
    over1year
    Fusicoccin-A Targets Cancerous Inhibitor of Protein Phosphatase 2A by Stabilizing a C-Terminal Interaction with 14-3-3. (PubMed, ACS Chem Biol)
    FC-A treatment of TNBC cells leads to the increased association of CIP2A with 14-3-3. We show that the composite interface between 14 and 3-3 and CIP2A's C-terminus can be targeted by the PPI stabilizer FC-A, providing a new interface that could potentially be exploited to modulate CIP2A's activity.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CIP2A (Cellular Inhibitor Of PP2A)
    over1year
    Prodigiosin inhibits the proliferation of glioblastoma by regulating the KIAA1524/PP2A signaling pathway. (PubMed, Sci Rep)
    Furthermore, it was verified that prodigiosin inhibited the KIAA1524/PP2A/Akt axis in vivo in the LN229 xenograft model. These data improve the understanding of the anticancer effects of prodigiosin and further highlight the potential of prodigiosin for the development of anti-glioma drugs.
    Journal
    |
    TP53 (Tumor protein P53) • CIP2A (Cellular Inhibitor Of PP2A) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    TP53 expression
    over1year
    Protein Phosphatase 2a Inhibits Gastric Cancer Cell Glycolysis by Reducing MYC Signaling. (PubMed, Cell Biochem Biophys)
    Importantly, inhibition of PP2A activity by genetic silencing of PPP2R5A resulted in a growth advantage, which can be largely compromised by the addition of the glycolysis inhibitor 2-Deoxy-D-glucose, suggesting a glycolysis-dependent effect of PP2A in gastric cancer...Ectopic expression of a phosphorylation-mutant c-Myc resistant to PP2A (MycT58A) restored the inhibitory effect of FTY-720 and DT-061 on lactate production and glucose uptake. Furthermore, there was a close association between SET and CIP2A expression and c-Myc gene signatures in gastric cancer samples. Collectively, this study provides strong evidence of the involvement of PP2A in the Warburg effect and indicates that it could be a novel antitumor strategy to target tumor metabolism in gastric cancer.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CIP2A (Cellular Inhibitor Of PP2A)
    |
    DT-061
    over1year
    m6A modification-mediated lncRNA TP53TG1 inhibits gastric cancer progression by regulating CIP2A stability. (PubMed, Cancer Sci)
    TP53TG1 interacts with cancerous inhibitor of protein phosphatase 2A (CIP2A) and triggers its ubiquitination-mediated degradation, resulting in the inhibition of PI3K/AKT pathway. These results suggest that TP53TG1 plays an important role in inhibiting the progression of GC and provides a crucial target for GC treatment.
    Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A) • ALKBH5 (AlkB Homolog 5, RNA Demethylase)
    |
    TP53 expression
    over1year
    Reciprocal regulation of CIP2A and AR expression in prostate cancer cells. (PubMed, Discov Oncol)
    The reduction of CIP2A expression also enhanced the sensitivity of PCa cells toward Enzalutamide treatment...In summary, our data showed the existence of a novel regulation between CIP2A and AR protein levels, which is critical for promoting PCa malignancy. Thus, CIP2A could serve as a therapeutic target for PCa.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PLK1 (Polo Like Kinase 1) • CIP2A (Cellular Inhibitor Of PP2A)
    |
    MYC expression • AR expression • CIP2A elevation
    |
    Xtandi (enzalutamide capsule)
    over1year
    Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients. (PubMed, J Clin Med)
    (4) Because the studied genes (BCL2, PP2A, CIP2A, and WT1) are participating in cell proliferation and death, the findings show that the examined genes are significant to understand the efficacy of various therapies. Furthermore, it was found that there was a clear effect of the clinic-based strategic treatment on hematological indicators such as WBCs, lymphocytes, neutrophils, and platelet counts.
    Journal • Combination therapy • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • WT1 (WT1 Transcription Factor) • CIP2A (Cellular Inhibitor Of PP2A)
    |
    BCL2 expression
    |
    imatinib • hydroxyurea
    over1year
    Metformin and Nightly Fasting in Women With Early Breast Cancer (clinicaltrials.gov)
    P2b, N=120, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2022 --> Jan 2023
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MCL1 (Myeloid cell leukemia 1) • CIP2A (Cellular Inhibitor Of PP2A) • GSK3B (Glycogen Synthase Kinase 3 Beta) • IGFBP3 (Insulin-like growth factor binding protein 3) • CRP (C-reactive protein)
    almost2years
    Metformin and Nightly Fasting in Women With Early Breast Cancer (clinicaltrials.gov)
    P2b, N=120, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Jul 2022 --> Oct 2022
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • MCL1 (Myeloid cell leukemia 1) • CIP2A (Cellular Inhibitor Of PP2A) • GSK3B (Glycogen Synthase Kinase 3 Beta) • IGFBP3 (Insulin-like growth factor binding protein 3) • CRP (C-reactive protein)
    almost2years
    Overexpression of cancerous inhibitor of PP2A (CIP2A) in acute myeloid leukemia. (PubMed, Expert Rev Hematol)
    In multivariate analysis, CIP2A overexpression was an independent adverse prognostic factor that negatively affected DFS and OS (p<0.001, HR:2.8,95%CI:1.7-4.7 and p=0.002, HR:1.8; 95%CI:1.2-2.65, respectively). CIP2A overexpression is a useful prognostic marker in AML.
    Journal
    |
    CD34 (CD34 molecule) • CIP2A (Cellular Inhibitor Of PP2A)
    almost2years
    LINC00665: An Emerging Biomarker for Cancer Diagnostics and Therapeutics. (PubMed, Cells)
    LINC00665 is closely associated with the effects of anticancer drugs, including gefitinib and cisplatin in non-small cell lung cancer, gemcitabine in cholangiocarcinoma, and cisplatin-paclitaxel in breast cancer. This work systematically summarizes the diagnostic and prognostic values of LINC00665 in various tumors, and comprehensively analyzes the molecular regulatory mechanism related to LINC00665, which is expected to provide clear guidance for future research.
    Review • Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A) • TGFB1 (Transforming Growth Factor Beta 1) • LINC00665 (Long Intergenic Non-Protein Coding RNA 665)
    |
    cisplatin • gefitinib • gemcitabine • paclitaxel
    almost2years
    (+)-Cyanidan-3-ol inhibits epidermoid squamous cell carcinoma growth via inhibiting AKT/mTOR signaling through modulating CIP2A-PP2A axis. (PubMed, Phytomedicine)
    Our study suggests that PP2A activation is an effective strategy for SCSC treatment and the CD-3 and mTORi combination may serve as a promising treatment for SCSC.
    Journal
    |
    CIP2A (Cellular Inhibitor Of PP2A)